Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)
Open Access

PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY

Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, Ismaheel Lawal, Otto Knoesen, Johncy Mahapane, Cindy Davis, Florette Reyneke, Alex Maes, Clemens Kratochwil, Thabo Lengana, Frederik Giesel, Christophe Van de Wiele and Alfred Morgenstern
Journal of Nuclear Medicine May 2019, jnumed.119.229229; DOI: https://doi.org/10.2967/jnumed.119.229229
Mike Sathekge
1 University of Pretoria, South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Bruchertseifer
2 European Commission, Joint Research Centre, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariza Vorster
1 University of Pretoria, South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ismaheel Lawal
1 University of Pretoria, South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otto Knoesen
3 Nuclear Technology Products (NTP), South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johncy Mahapane
1 University of Pretoria, South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cindy Davis
1 University of Pretoria, South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florette Reyneke
1 University of Pretoria, South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Maes
4 Katholieke UniversityLeuven, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Kratochwil
5 University Hospital Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thabo Lengana
1 University of Pretoria, South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Giesel
5 University Hospital Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Van de Wiele
6 Ghent University, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Morgenstern
3 Nuclear Technology Products (NTP), South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Metastatic prostate carcinoma over-expresses the prostate specific membrane antigen (PSMA) making this antigen a suitable target for radioligand therapy of the disease. Here we report on our experience in a series of 73 castrate resistant prostate carcinoma patients treated with 225Ac-PSMA-617, identifying variables predictive for overall and progression free survival following 225Ac-PSMA-617 treatment. Methods: 225Ac-PSMA-617 was administered to patients with mCRPC who had exhausted available therapy options for their disease. Full blood count, glomerular filtration rate and liver function test were obtained at baseline and on follow-up for evaluation of toxicity. 68Ga-PSMA PET/CT was obtained at baseline, prior to every treatment cycle and on follow-up for patients’ selection for treatment, to determine the activity of treatment agent to be adminsitered and for response assessment. Serial (prostate specific antigen) PSA was obatianed for PSA response assessment. Results: Seventy-three men (mean age=69 years, range:45-85) with mCRPC were treated with 210 cycles of 225Ac-PSMA-617. In 70% of patients, a PSA decline of ≥50% was obtained while 83% of patients had any PSA decline. In 29% of patients, all lesions on 68Ga-PSMA-PET resolved in response to treatment. During follow-up, 23 patients experienced disease progression while 13 patients died from their disease. The estimated median progression free survival (PFS) and overall survival (OS) were 15.2 months (95% CI: 13.1 – 17.4) and 18 months (95% CI: 16.2 – 19.9) respectively. On univariate analyses factors such as baseline PSA, any PSA decline, PSA decline ≥50%, prior chemotherapy, prior radiation therapy, baseline hemoglobin level were associated with longer PFS and OS (all p<0.05). On multivariate analyses, only prior Lu-PSMA therapy and a PSA decline ≥50% remained significant in their association with a longer PFS while only PSA decline ≥50% remained significantly associated with OS. Xerostomia was seen in 85% of patients, none was severe enough to warrant discontinuing treatment. Anaemia was seen in 27 patients, no patients with grade IV bone marrow toxicity was seen. Renal failure grade III-IV was seen in five patients with baseline renal impairement. Conclusion: In this study, a PSA decline of > 50% proved significantly associated with OS and PFS in multivariate analysis following treatment with 225Ac-PSMA-617. Furthermore, previous 177Lu-PSMA treatment was negatively associated with PFS in both uni- and multivariate analysis.

  • Radionuclide Therapy
  • Actinium-225
  • PSA response
  • PSMA
  • prostate carcinoma
  • radioligand therapy
  • Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (9)
Journal of Nuclear Medicine
Vol. 64, Issue 9
September 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY
Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, Ismaheel Lawal, Otto Knoesen, Johncy Mahapane, Cindy Davis, Florette Reyneke, Alex Maes, Clemens Kratochwil, Thabo Lengana, Frederik Giesel, Christophe Van de Wiele, Alfred Morgenstern
Journal of Nuclear Medicine May 2019, jnumed.119.229229; DOI: 10.2967/jnumed.119.229229

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY
Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, Ismaheel Lawal, Otto Knoesen, Johncy Mahapane, Cindy Davis, Florette Reyneke, Alex Maes, Clemens Kratochwil, Thabo Lengana, Frederik Giesel, Christophe Van de Wiele, Alfred Morgenstern
Journal of Nuclear Medicine May 2019, jnumed.119.229229; DOI: 10.2967/jnumed.119.229229
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Cyclotron-Produced 132La as a PET Imaging Surrogate for Therapeutic 225Ac
  • Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer
  • Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted {alpha}-particle therapy
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • The added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer
Show more Clinical Investigations (Human)

Clinical (Radionuclide Therapy)

  • [177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial
  • Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
Show more Clinical (Radionuclide Therapy)

Similar Articles

Keywords

  • radionuclide therapy
  • actinium-225
  • PSA response
  • PSMA
  • prostate carcinoma
  • radioligand therapy
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire